共 127 条
[1]
Ferrara N(2004)Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 581-611
[2]
Erber R(2004)Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms FASEB J 18 338-340
[3]
Thurnher A(2005)Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis Cytokine Growth Factor Rev 16 159-178
[4]
Katsen AD(2008)Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 592-603
[5]
Groth G(2012)Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies J Clin Oncol 30 4026-4034
[6]
Kerger H(2013)BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer Mol Cancer Ther 12 992-1001
[7]
Hammes H-P(2008)BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res 68 4774-4782
[8]
Presta M(2011)Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers Xenobiotica 41 297-311
[9]
Dell’Era P(2009)Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors Clin Cancer Res 16 311-319
[10]
Mitola S(2014)Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial Lancet Oncol 15 143-155